Zacks: Analysts Expect Travere Therapeutics, Inc. (NASDAQ:TVTX) Will Announce Earnings of -$0.89 Per Share

Equities research analysts expect Travere Therapeutics, Inc. (NASDAQ:TVTXGet Rating) to report earnings of ($0.89) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Travere Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.78) and the lowest estimate coming in at ($1.03). Travere Therapeutics posted earnings of ($0.96) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 7.3%. The firm is expected to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Travere Therapeutics will report full year earnings of ($3.68) per share for the current fiscal year, with EPS estimates ranging from ($4.31) to ($2.64). For the next year, analysts forecast that the company will post earnings of ($3.19) per share, with EPS estimates ranging from ($4.48) to ($1.12). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Travere Therapeutics.

Travere Therapeutics (NASDAQ:TVTXGet Rating) last issued its quarterly earnings results on Thursday, February 24th. The company reported ($0.84) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.12). Travere Therapeutics had a negative return on equity of 55.22% and a negative net margin of 79.16%. The business had revenue of $57.25 million during the quarter, compared to analyst estimates of $56.40 million. During the same quarter last year, the company posted ($2.37) EPS. Travere Therapeutics’s quarterly revenue was up 12.3% compared to the same quarter last year.

Several research firms have recently issued reports on TVTX. Piper Sandler initiated coverage on shares of Travere Therapeutics in a research note on Wednesday, March 30th. They set an “overweight” rating and a $42.00 target price on the stock. Zacks Investment Research lowered Travere Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, HC Wainwright initiated coverage on shares of Travere Therapeutics in a report on Monday, February 28th. They issued a “buy” rating and a $45.00 price target for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Travere Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $34.11.

In other news, SVP Elizabeth E. Reed sold 1,350 shares of Travere Therapeutics stock in a transaction on Monday, January 31st. The stock was sold at an average price of $27.40, for a total transaction of $36,990.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP William E. Rote sold 1,875 shares of the business’s stock in a transaction dated Monday, January 24th. The shares were sold at an average price of $24.98, for a total transaction of $46,837.50. The disclosure for this sale can be found here. Insiders have sold 22,069 shares of company stock worth $572,764 over the last 90 days. 4.31% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Walleye Capital LLC acquired a new stake in shares of Travere Therapeutics during the 4th quarter valued at approximately $1,338,000. Wells Fargo & Company MN raised its stake in shares of Travere Therapeutics by 31.1% during the 4th quarter. Wells Fargo & Company MN now owns 60,425 shares of the company’s stock worth $1,876,000 after buying an additional 14,319 shares during the last quarter. Allianz Asset Management GmbH purchased a new stake in shares of Travere Therapeutics in the 4th quarter worth about $1,851,000. Deutsche Bank AG grew its stake in Travere Therapeutics by 16.7% in the 4th quarter. Deutsche Bank AG now owns 397,646 shares of the company’s stock valued at $12,343,000 after acquiring an additional 56,799 shares during the last quarter. Finally, California State Teachers Retirement System increased its holdings in Travere Therapeutics by 3.1% during the 4th quarter. California State Teachers Retirement System now owns 78,416 shares of the company’s stock valued at $2,434,000 after acquiring an additional 2,386 shares in the last quarter.

Shares of TVTX traded up $0.14 during trading hours on Wednesday, hitting $30.15. The stock had a trading volume of 9,185 shares, compared to its average volume of 713,888. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of -9.95 and a beta of 0.74. The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.64 and a current ratio of 4.70. The firm has a 50-day moving average price of $26.84 and a 200 day moving average price of $27.57. Travere Therapeutics has a fifty-two week low of $12.75 and a fifty-two week high of $31.65.

About Travere Therapeutics (Get Rating)

Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.

Recommended Stories

Get a free copy of the Zacks research report on Travere Therapeutics (TVTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.